Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2013-12-10 Regulatory Filings
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It reports an update from the Tel-Aviv Stock Exchange about the company's removal from a stock index. The document is short (4351 characters) and primarily serves as a regulatory announcement rather than a detailed financial report. It does not contain financial statements or substantive financial data. It also includes a signature page and a cautionary statement typical for regulatory filings. Given these characteristics, this document fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2013-12-10 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It reports an immediate update regarding a legal matter involving a request for compromise or settlement with the court and the Israeli Securities Authority. The document includes a description of the company, contact information, and a cautionary statement about forward-looking statements. It does not contain financial statements or detailed financial analysis. The document is relatively short (4734 characters) and serves as a regulatory update rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2013-12-10 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd. It reports an immediate event: a request for a compromise or settlement with the court regarding warrant expiration dates and shareholder meetings. The document is an immediate report of a corporate event, not a full financial report or earnings release. It does not contain financial statements or detailed financial analysis. It is not a proxy solicitation, dividend notice, or management change announcement. The document is a regulatory filing reporting a material event as required by the SEC for foreign issuers. Therefore, it fits best under Regulatory Filings (RNS). The document length is under 5,000 characters, but it contains substantive information rather than just an announcement of a report publication, so it is not RPA. The presence of signatures and the nature of the content confirm it is a regulatory filing.
2013-12-09 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It reports the postponement of an extraordinary general meeting due to failure to meet the legal quorum. The content is an immediate report published on the Tel-Aviv Stock Exchange, providing details about the meeting postponement and instructions for warrant holders. There are no financial statements, earnings data, or detailed management discussion. The document is a regulatory announcement about a corporate event rather than a full report or financial disclosure. It is not an Annual Report, Interim Report, Earnings Release, or any detailed financial or governance report. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2013-12-05 English
FORM 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filing by XTL Biopharmaceuticals Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It contains interim financial statements as of September 30, 2013, including a Board of Directors' report, reviewed condensed consolidated financial statements, separate financial information, and an interim report on internal control effectiveness. The content includes detailed financial data and management discussion for a period shorter than a full fiscal year (nine months ended September 30, 2013). This matches the definition of an Interim / Quarterly Report (IR). The document is substantive and not merely an announcement or certification, and it is not a full annual report (10-K) or other filing type. Therefore, the correct classification is IR with high confidence.
2013-11-29 English
FORM 6-K
Transaction in Own Shares Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd. It reports a change in treasury shares, detailing sales of shares by a subsidiary. The document includes transaction dates, share quantities, and prices, but does not contain comprehensive financial statements or detailed financial analysis. It is an immediate report about share transactions, not a full financial report or earnings release. The content fits the description of a Transaction in Own Shares (POS) filing, which reports company buybacks or sales of its own shares. The document length is over 5,000 characters and contains detailed transaction data, supporting classification as POS rather than a brief announcement or regulatory filing.
2013-11-26 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.